CTOs on the Move


 
Noom is the world`s leading behavior change company, disrupting the weight loss and healthcare industries. By combining the power of artificial intelligence, mobile tech, and psychology with the empathy of over 1,000 personal coaches, Noom helps people live healthier lives by changing their long-term habits. More than 50 million people have benefited from Noom`s behavior change courses, including its virtual diabetes prevention program, which was the first of its kind to be recognized by the CDC. The Noom platform is already being used by leading healthcare and pharmaceutical companies to improve treatment outcomes for patients worldwide. The company is headquartered ...
  • Number of Employees: 1K-5K
  • Annual Revenue: > $1 Billion
  • www.noom.com
  • 229 West 28th Street Floor 9
    New York, NY USA 10001
  • Phone: 800.910.7375

Executives

Name Title Contact Details
Takeaki Chijiiwa
Director, Information Security Profile
Richard Friedman
Chief Technology Officer Profile

Funding

Noom raised $58M on 05/06/2019
Noom raised $540M on 05/25/2021

Similar Companies

Adnexus Therapeutics, Inc.

Adnexus Therapeutics, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Waltham, MA. To find more information about Adnexus Therapeutics, Inc., please visit www.adnexustx.com

Benefit and Risk Management Services

Benefit and Risk Management Services is a Folsom, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mirth Corporation

Mirth Corporation is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Next Health

Next Health is an immunity health and wellness center specializing in IV Therapy, Cryotherapy, NAD Therapy and COVID Testing. Walk-ins are welcome.

Bioatla

BioAtla was founded in 2007 and employs deep expertise in protein engineering to develop better monoclonal antibody and other protein therapeutics. Our suite of proprietary technologies (protected by more than 70 issued patents and patent applications) has enabled us to develop dozens of novel therapeutic proteins for our partners and our own pipeline. We accelerate the process from target discovery to manufacturing and preclinical studies by creating drugs with more selective targeting, greater affinity, and more cost-efficient and predictable manufacturing. In the process we also create valuable, protectable IP that gives our partners significant competitive advantage. The culmination of our protein evolution technologies is our Conditionally Active Biologics (CAB)platform. Monoclonal antibodies or enzymes can be engineered for selective conditional activation, i.e. the protein`s functions are designed to modulate with changes in microphysical conditions (e.g., pH level, oxidation, temperature, pressure concentration, presence of certain ions, hydrophobicity and competing protein binding). Tumors and other kinds of diseased tissue give rise to unique localized conditions distinct from normal tissue. CAB designed monoclonal antibodies can be programmed to deliver an ADC payload and/or recruit the immune response to specific sites and conditions in the body.